A Ph2 Randomized Trial to Evaluate the Safety Preliminary Efficacy and Biomarker Response of Host Directed Therapies Added to Rifabutin-modified Standard Therapy in Adults With Drug-Sensitive Smear-Positive Pulmonary TB

Trial Profile

A Ph2 Randomized Trial to Evaluate the Safety Preliminary Efficacy and Biomarker Response of Host Directed Therapies Added to Rifabutin-modified Standard Therapy in Adults With Drug-Sensitive Smear-Positive Pulmonary TB

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 May 2017

At a glance

  • Drugs Auranofin (Primary) ; CC 11050 (Primary) ; Colecalciferol (Primary) ; Everolimus (Primary) ; Rifabutin
  • Indications Pulmonary tuberculosis
  • Focus Adverse reactions
  • Acronyms TBHDT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 May 2017 Status changed from not yet recruiting to recruiting.
    • 28 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top